MBX Biosciences to Participate in March Investor Conferences
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in March 2025.
The company's President and CEO, Kent Hawryluk, will deliver a podium presentation at the TD Cowen 45th Annual Healthcare Conference in Boston on March 3, 2025, from 10:30-11:00 a.m. ET, along with one-on-one meetings. Additionally, MBX will participate in the Jefferies Biotech on the Beach Summit in Miami Beach on March 12th, featuring one-on-one meetings.
Webcasts of the presentations will be available on the investors section of MBX Biosciences' website, with replay access available approximately two hours post-event and archived for roughly 90 days.
MBX Biosciences (Nasdaq: MBX), un'azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrine e metabolici, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
Il Presidente e CEO dell'azienda, Kent Hawryluk, terrà una presentazione al TD Cowen 45th Annual Healthcare Conference a Boston il 3 marzo 2025, dalle 10:30 alle 11:00 ET, insieme a incontri individuali. Inoltre, MBX parteciperà al Jefferies Biotech on the Beach Summit a Miami Beach il 12 marzo, con incontri individuali.
Le registrazioni delle presentazioni saranno disponibili nella sezione investitori del sito web di MBX Biosciences, con accesso alla riproduzione disponibile circa due ore dopo l'evento e archiviato per circa 90 giorni.
MBX Biosciences (Nasdaq: MBX), una compañía biofarmacéutica en etapa clínica especializada en terapias peptídicas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en dos importantes conferencias para inversores en marzo de 2025.
El presidente y CEO de la empresa, Kent Hawryluk, realizará una presentación en el TD Cowen 45th Annual Healthcare Conference en Boston el 3 de marzo de 2025, de 10:30 a 11:00 a.m. ET, junto con reuniones uno a uno. Además, MBX participará en el Jefferies Biotech on the Beach Summit en Miami Beach el 12 de marzo, con reuniones uno a uno.
Las transmisiones de las presentaciones estarán disponibles en la sección de inversores del sitio web de MBX Biosciences, con acceso a la repetición disponible aproximadamente dos horas después del evento y archivada durante unos 90 días.
MBX 바이오사이언스 (Nasdaq: MBX)는 내분비 및 대사 장애를 위한 정밀 펩타이드 치료제를 전문으로 하는 임상 단계의 바이오제약 회사로, 2025년 3월에 두 개의 주요 투자자 회의에 참가한다고 발표했습니다.
회사의 회장 겸 CEO인 Kent Hawryluk는 2025년 3월 3일 오전 10:30부터 11:00까지 TD Cowen 제45회 연례 의료 회의에서 발표를 진행하며, 일대일 미팅도 진행합니다. 또한, MBX는 3월 12일 마이애미 비치에서 열리는 Jefferies Biotech on the Beach Summit에 참가하여 일대일 미팅을 가질 예정입니다.
발표의 웹캐스트는 MBX 바이오사이언스 웹사이트의 투자자 섹션에서 이용할 수 있으며, 이벤트 종료 후 약 두 시간 후에 재생할 수 있고 대략 90일 동안 아카이브됩니다.
MBX Biosciences (Nasdaq: MBX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025.
Le président et PDG de l'entreprise, Kent Hawryluk, fera une présentation lors de la TD Cowen 45th Annual Healthcare Conference à Boston le 3 mars 2025, de 10h30 à 11h00 ET, ainsi que des réunions individuelles. De plus, MBX participera au Jefferies Biotech on the Beach Summit à Miami Beach le 12 mars, avec des réunions individuelles.
Les webcasts des présentations seront disponibles dans la section investisseurs du site Web de MBX Biosciences, avec un accès à la rediffusion disponible environ deux heures après l'événement et archivé pendant environ 90 jours.
MBX Biosciences (Nasdaq: MBX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf präzise Peptidtherapien für endokrine und Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben.
Der Präsident und CEO des Unternehmens, Kent Hawryluk, wird am 3. März 2025 von 10:30 bis 11:00 Uhr ET eine Podiumspräsentation auf der TD Cowen 45th Annual Healthcare Conference in Boston halten und Einzelgespräche führen. Darüber hinaus wird MBX am Jefferies Biotech on the Beach Summit am 12. März in Miami Beach teilnehmen, ebenfalls mit Einzelgesprächen.
Webcasts der Präsentationen werden im Investorenbereich der Website von MBX Biosciences verfügbar sein, mit Zugang zur Wiederholung etwa zwei Stunden nach der Veranstaltung und für ungefähr 90 Tage archiviert.
- None.
- None.
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences:
TD Cowen 45th Annual Healthcare Conference
Date: Monday, March 3, 2025
Format: Podium Presentation and 1x1 meetings
Time: 10:30 a.m. – 11:00 a.m. ET
Location: Boston, MA
Jefferies Biotech on the Beach Summit
Date: Wednesday, March 12th
Format: 1x1 meetings
Location: Miami Beach, FL
Presentation webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When and where will MBX Biosciences present at the TD Cowen Healthcare Conference in March 2025?
What type of sessions will MBX participate in at the Jefferies Biotech Summit in March 2025?
How long will the MBX Biosciences conference presentation webcasts be available online?
Where can investors access MBX Biosciences' March 2025 conference presentation webcasts?
